Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

After unveiling a new drug substance facility in North Carolina in December, Amgen is doubling down on expanding its U.S. | ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

With the threat of Trump administration's tariffs swirling and biopharma companies bracing for impact, many are announcing ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

While much of the conversation around the Trump administration’s potential pharmaceutical import tariffs has leaned heavily ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Pharmacy benefit managers (PBMs) are up to bat in the perpetual blame game between PBMs and the pharmaceutical industry. | ...